Yissum is the technology transfer company of the Hebrew university of Jerusalem (HUJI) . The Hebrew University, Israel’s leading academic institution, carries out more than one third of all academic scientific research in Israel and forty three percent of Israeli biotech research.
Through Yissum’s efforts, many products originating in Hebrew University technology are sold worldwide each year; 6,100 patents have been registered covering 1,750 inventions; 480 technologies have been licensed and 65 companies spun out. Currently Yissum offers for licensing more than 250 projects in the biotech and agriculture areas. Yissum also owns equity in approximately 30 companies in the biotech areas in differnet stages of development and offers collaborations with most of them.
Yissum which was founded in 1964, manages all activities relating to the protection and commercialization of inventions and discoveries made by HUJI researchers. In addition Yissum manages Hebrew University's research services, which provides clients access to the world-class expertise of the University's researchers.
Yissum has a successful track record and gained global recognition, by creating partnerships with business and industry worlwide leaders (e.g. Roche, Novartis, J&J, Teva). Some Yissum products which have reached the market include: Exelon (developed and marketed by Novartis), Doxil (Caeylx)(marketed by J&J and Scharing Plough) Periochip (developed and marketed by Dexxon), and Cationorm ( developed by Novagali Pharma).
Yissum currently offers for licensing over 200 technologies in the following fields: Drug Delivery, CNS, Metabolic Diseases, Cancer, Medical Devices, siRNA, bio-crop protection and many more.
Contact DetailsAddress: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.. Hi-Tech Park, Edmond J. Safra Campus
Givat-Ram, P.O. Box 39135, Jerusalem 91390 Israel
Email: email@example.com Internet site: www.yissum.co.il
Exhibition RepresentativesName: Yaacov Michlin, CEO
Name: Shoshi Keynan
Category: Drug Delivery, CNS, Oncology